• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC Feb 1, 2010.
Published in final edited form as:
PMCID: PMC2746251
NIHMSID: NIHMS130390

Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors

Matthias Nahrendorf, MD, PhD,*,1,2 Peter Waterman, BS,*,1,2 Greg Thurber, PhD,1 Kevin Groves, PhD,3 Milind Rajopadhye, PhD,3 Peter Panizzi, PhD,1,2 Brett Marinelli, BS,1 Elena Aikawa, MD PhD,2 Mikael J Pittet, PhD,1,2 Filip K Swirski, PhD,1,2 and Ralph Weissleder, MD, PhD1,2

Abstract

Objective

Proteases are emerging biomarkers of inflammatory diseases. In atherosclerosis, these enzymes are often secreted by inflammatory macrophages, digest the extracellular matrix of the fibrous cap and destabilize atheromata. Protease function can be monitored with protease activatable imaging probes and quantitated in vivo by fluorescence molecular tomography (FMT). To address two major constraints currently associated with imaging of murine atherosclerosis (lack of highly sensitive probes and absence of anatomical information), we compared protease sensors (PS) of variable size and pharmacokinetics and co-registered FMT datasets with computed tomography (FMT-CT).

Methods and results

Co-registration of FMT and CT was achieved with a multimodal imaging cartridge containing fiducial markers detectable by both modalities. A high-resolution CT angiography protocol accurately localized fluorescence to the aortic root of atherosclerotic apoE−/− mice. To identify suitable sensors, we first modeled signal kinetics in-silico and then compared three probes with identical oligo-L-lysine cleavage sequences: PS-5, 5nm in diameter containing 2 fluorochromes , PS-25, a 25nm version with an elongated lysine chain and PS-40, a polymeric nanoparticle. Serial FMT-CT showed fastest kinetics for PS-5 but, surprisingly, highest fluorescence in lesions of the aortic root for PS-40. PS-40 robustly reported therapeutic effects of atorvastatin, corroborated by ex vivo imaging and qPCR for the model protease cathepsin B.

Conclusions

FMT-CT is a robust and observer-independent tool for non-invasive assessment of inflammatory murine atherosclerosis. Reporter-containing nanomaterials may have unique advantages over small molecule agents for in vivo imaging.

Keywords: FMT-CT, molecular imaging, atherosclerosis, protease activity, inflammation

Introduction

A thin fibrous cap, presence of macrophages and foam cells, and increased activity of proteases are hallmarks of atherosclerotic lesions at risk for causing myocardial infarction and stroke.1 Typically, the fibrous cap and the endothelial layer are damaged due to heightened inflammatory activity, thus exposing the thrombogenic plaque core to platelets and coagulation factors in the blood stream. This triggers thrombotic occlusion of the artery followed by ischemic injury of downstream tissue.1 Positive remodeling of the artery may obscure detection of inflamed plaques as the vessel lumen can be virtually unchanged, while some protruding plaques that cause significant stenosis on angiography are fairly stable.2 Hence, protease activity in a lesion may have a higher predictive value for ischemic events than reported for the anatomic degree of stenosis.3

Protease presence in atherosclerotic lesions has been imaged with radiolabeled small molecule inhibitors 4, 5 and more recently with a MRI detectable Gd chelate attached to an affinity peptide targeting MMPs.6 Fluorescent protease sensors (PS), which are injected in an inactive form and only emit signal after cleavage of a peptide sequence specific to their target enzyme, have been used to image protease activity.7 Cysteine proteases are mainly expressed by monocytes/macrophages,8, 9 cells which orchestrate atherosclerotic lesion development and destabilization. They promote digestion of extracellular matrix, leukocyte transmigration, apoptosis and neovascularization in atheromata,1, 10 and can thus serve as imaging biomarkers for plaques with a high risk of thrombotic complication.11

Fluorescence Molecular Tomography (FMT) is emerging as a quantitative modality for non-invasive whole mouse imaging,12 and can be used to detect and quantitate inflammatory protease activity.7, 13 High-throughput capabilities with scan times of <5 minutes, cost-effectiveness, high sensitivity, absence of radiation and simultaneous imaging of multiple biomarkers in spectrally resolved channels are advantages that promote the use of FMT.14 However, there are two challenges to more widespread application in imaging of murine atherosclerosis. First, similar as seen in stand-alone PET imaging of atherosclerosis, there is often a paucity of anatomic information in optical-only FMT data sets (unless additional imaging probes capable of reporting structural information are co-injected). Since atherosclerotic plaques are small and vary in distribution, their accurate localization in such data sets is challenging. To overcome this limitation, we have developed hybrid FMT-CT protocols, similarly as is done in combined PET-CT imaging.1517 Second, we address the lack of molecular probes with optimized signal- and pharmakokinetics for in vivo FMT imaging of atherosclerotic plaques. While the targeting strategy of PS has been validated,8, 11 the influence of probe design on signal kinetics and sensitivity has not yet been investigated. In particular, size effects of nanoparticulate sensors have been less well studied. Based on in-silico modeling, we synthesized, characterized and compared three differently sized nano-sensors activated by cysteine proteases. To compare the attributes of PS that are different in design and size but share the cleavage peptide sequence that triggers their activation, we serially imaged atherosclerotic lesions in apoE−/− mice using non-invasive hybrid FMT-CT. We further investigated if the lead compound has the dynamic range and sensitivity to detect benchmark anti-atherosclerotic treatment with atorvastatin.

Methods

Agent synthesis

A schematic overview of agent design and mechanism of activation is given in Figure 1A–B. We combined the epsilon-protected lysine oligo-peptides (1.5 µmol, Tufts University Core) and VivoTag-S680 (Visen Medical) in 100 µL of N,N-dimethylformamide (DMF) with N-methylmorpholine (NMM) and N,N-dimethylaminopyridine (DMAP) to synthesize a fluorochrome labeled peptide (in the following termed FLP). The labeled peptide was isolated by centrifugation and purified by HPLC. For synthesis of PS-5, FLP was combined with mPEG-NH2. 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and hydroxybenzotriazole were added to the solution. After deprotection of the epsilon-amine, crude PS-5 was purified by reversed phase HPLC and characterized by SEC HPLC. The 25 nm sized agent (PS-25) was formed by controlled precipitation in alkaline polymer solution. For synthesis of PS-40, we combined a solution of amine-functionalized polymeric nanoparticles18 (~40 nm particles, ~200 amines / particle) in MES with 0.25 µmol of the above described fluorochrome labeled peptide. The nanoparticles were washed with ammonium bicarbonate and then purified by gel filtration chromatography using Biogel P100 (Biorad). Approximately 5–6 FLP were conjugated to each nanoparticle.

Figure 1
Probe design and characterization

Target enzymes

To evaluate the target profile, we incubated PS-25 with a panel of enzymes including key proteases present in atherosclerotic plaques. PS-25 (0.5 mM) was mixed with enzymes (20 nM) in appropriate buffers at room temperature. The following enzymes were purchased from R&D, Sigma or Calbiochem: cathepsin B, D, G, K, L, S, plasmin, trypsin and uPA. Reaction progress was monitored at excitation/emission wavelengths of 663/691 using a Gemini-XS plate reader.

Modeling of in vivo sensor activation

A mechanistic model was developed for activation of differently sized PS and resulting fluorochrome concentrations in atherosclerotic plaque. Details of the model are provided in the supplemental information.

Murine model

This study used 40–45 week old apoE−/− mice (Jackson Laboratories) fed a high cholesterol diet (HCD, Harlan; 0.2% total cholesterol, 5 mice received HCD enriched with 0.01% wt/wt of atorvastatin19). These mice develop atherosclerotic lesions that resemble human disease; and although plaque rupture is not frequently reported, monocytes, macrophages and foam cells are present and produce proteases (reviewed in ref20). The accentuated inflammation in the aortic root has been used as a model system in several other imaging studies.15, 21, 22 For determination of cholesterol levels, a blood sample of 500 µL was collected at the time of sacrifice and serum assayed for cholesterol by colorimetry (Raichem). The institutional subcommittee on research animal care approved all animal studies.

Blood half life of PS-5, PS-25 and PS-40

To determine the blood half-life of PS-5, PS-25 and PS-40, mice received an IV injection of 5 nanomoles of the agent via tail vein (6 C57BL/6 mice and also in 3–5 apoE−/− mice per agent). Bilateral retro-orbital bleeds were performed immediately and 2, 4, 8, 24 and 48 hours after injection. 50 µl of blood was drawn from alternating orbita using non-heparinized microcapillary tubes and collected into 50 µl of heparin. Equal volumes of heparinized blood and DMSO were incubated to activate the probe. Fluorescence of blood samples was then measured on a home built system (excitation/emission 680/700 nm).

Macroscopic ex vivo fluorescence reflectance imaging

Aortas were harvested 24 hours after injection of respective sensor and imaged with a fluorescence microscope at 4x magnification (OV-110, Olympus). Six apoE−/− mice were injected with PS-5, 4 with PS-25 and 3 with PS-40. In addition, 3 wild type mice on normal diet and 3 wild type mice that have been fed a diet high in cholesterol for 10 weeks were injected with each sensor. Two apoE−/− mice were co-injected with either PS-5 or PS-40 and in addition with a version of PS-25 that was synthesized with a spectrally resolved fluorochrome (VT750) to compare the regional activation profile of sensors. Light and near infrared fluorescence (NIRF) images were obtained in the 680 and 750 nm channels.

FMT-CT

We performed FMT-CT imaging at 680/700 nm excitation/emission wavelength in cohorts of mice at 2, 4, 8, 24 and 48 hours after injection of 5 nmol of respective PS using an FMT 2500 system (VisEn Medical) with an isotropic resolution of 1 mm. Each sensor was injected into 6–7 apoE−/− mice, 4–5 wild type mice on normal diet, and 3 wild type mice on high cholesterol diet. PS-40 was also injected into 5 apoE−/− mice treated with atorvastatin. Mice were anesthetized (Isoflurane 1.5 %, O2 2L/min) during imaging with a gas delivery system integrated into the multimodal imaging cartridge that holds the mouse during FMT and CT imaging. This cartridge facilitates co-registration of FMT to CT data through fiducial landmarks on its frame. Total imaging time for FMT acquisition was typically 5–8 minutes. Data were post-processed using a normalized Born forward equation to calculate three-dimensional fluorochrome concentration distribution. CT angiography immediately followed FMT to robustly identify the aortic root as the region of interest. The imaging cartridge lightly compressed the anesthetized mouse between optically translucent windows and thereby prevented motion during transfer to the CT (Inveon PET-CT, Siemens). The CT x-ray source operated at 80 kVp and 500 µA with an exposure time of 370 – 400 ms to acquire 360 projections. The effective 3D CT resolution was 80 µm isotropic. During CT acquisition, Isovue-370 was infused at 55 µL/min through a tail vein catheter. The CT reconstruction protocol performed bilinear interpolation, used a Shepp-Logan filter, and scaled pixels to Hounsfield units. We then imported data into OsiriX (The OsiriX foundation) to co-register FMT and CT images. Fiducials on the imaging cartridge were visualized and tagged in FMT and CT images with point markers to define their XYZ coordinates. Using these coordinates, data were re-sampled, rotated and translated to match the image matrices, and finally displayed in one hybrid image.

Microscopy

For comparison of PS activation to microscopic cathepsin B distribution in plaques, aortic roots were excised from 2 apoE−/− mice per sensor and embedded in OCT (Sakura). Serial 6 µm thick transversal sections were collected and stained with a primary antibody targeting the model protease cathepsin B (Santa Cruz), a biotinylated secondary antibody (Vector), streptavidin-texas red (Amersham) and mounting medium with DAPI (Vector). Cathepsin B signal and activation of the PS were assessed using an epifluorescence microscope (Eclipse 80i, Nikon).

Flow cytometry

To investigate the cellular signal contributions for each protease sensor, we assessed blood and aortic tissue fluorescence 24 hours after injection of PS-5, PS-25 and PS-40 into 1 apoE−/− mice per sensor. ApoE−/− mice were sacrificed and blood and aortas prepared as described previously. 9 For visualization of macrophages, monocytes, and neutrophils, cells were incubated with a cocktail of monoclonal antibodies against T cells (CD90-PE), B cells (B220-PE), NK cells (DX5-PE and NK1.1-PE), granulocytes (Ly-6G-PE), myeloid cells (CD11b-APC), macrophages/dendritic cells (F4/80-biotin-Strep-PerCP, I-Ab-biotin-Strep-PerCP and CD11c-biotin-Strep-PerCP, all from BD Biosciences,). Data were acquired on an LSRII (BD Biosciences) with 670/LP and 695/40 filter configuration to detect PS activation.

Quantitative PCR

As an independent validation, the translation of mRNA encoding cathepsin B was measured in apoE−/− mice with and without atorvastatin therapy. Multiplex quantitative PCR was performed on triplicate samples using Applied Biosystems TaqMan® Gene Expression Assays and the 7500 Fast Real-Time PCR System. Primers were obtained from Applied Biosystems (Mm01310506_m1). Results were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

Statistics

Results are expressed as mean±SEM. The data were tested for normality using the Kolmogorov-Smirnov test, and for equality of variances using the F test. Data were compared using the unpaired two-sided t-test. If either normality or equality of variances were rejected, the nonparametric Mann-Whitney test was used. For multiple comparisons, we used ANOVA followed by Bonferroni post test. The significance level in all tests was 0.05.

Results

In vitro characteristics of sensors

Figure 1A–B provides an overview of the structure and characterization of the three differently sized protease sensors. HPLC analysis confirmed calculated sizes of the sensors (Fig. 1C). The overall fluorescence intensity after activation was comparable for the three probes (Fig. 1D, E). However, PS-40 was quenched most efficiently likely due to its specific design in which multiple fluorochromes were attached to the nanoparticle (Fig. 1D). In vitro assaying provided cleavage efficiency for a number of enzymes involved in plaque destabilization (Fig. 1F). Highest fluorescence intensity was observed after incubation with cathepsin B.

Pharmacokinetics favor PS-40 for in vivo FMT

We first measured the blood half life of the three PS to investigate impact of agent size on the clearance from the blood pool. Each sensor was injected into 6 wild type mice, and blood was drawn at several time points. For PS-5 and PS-40, a one-compartment model best described the signal behavior over time. For PS-25, a two-compartment model was used because it better described the data points and a one-compartment model did not converge. The shortest blood half life was observed for PS-5, followed by PS-25 and PS-40 (5.5 ± 0.5 hrs, 13.1 ± 1.6 hrs, 19.0 ± 2.2 hrs, Fig. 2A). Blood half life was also determined in apoE−/− mice for each sensor. Values were in the 95% confidence interval of wild type values (6.3 hrs for PS-5, 13.7 hrs for PS-25, 18.9 hrs for PS-40).

Figure 2
Pharmacokinetics and ex vivo imaging of activation

Using the measured blood half life and reported values for the rate of probe uptake, the concentration of active dye in the aorta was modeled in-silico as a function of time (Fig. 2B and online supplement). PS-5 reached its maximum signal earliest due to its rapid clearance from the plasma. PS-40 had a longer blood half-life, gave a higher maximum signal, but took longer to accumulate. The clearance rate of PS-25 from the blood fit a biexponential decay model, as expected for hydrophilic molecules of this size.23 The plasma half life of PS-40 was predicted to give rise to the highest signal intensity. Therefore, even longer half lives were simulated to see if larger gains could be achieved. Modeling results indicate that these longer half life agents have diminishing returns. For instance, a 10-fold increase in the clearance half life would be required to double the signal intensity in plaque. These slow kinetics would likely increase the background signal. Given the marginal benefits of developing a sensor with such a long half life, we did not pursue its synthesis.

Ex vivo FRI shows activation profile in plaques

We then injected PS-5, PS-25 and PS-40 into wild type mice on normal and high fat diet and apoE−/− mice. Twenty four hours later, mice were sacrificed, their aortas excised, and ex vivo fluorescence in atherosclerotic plaques and non-diseased vessel wall was compared. Activation of all sensors was higher in atherosclerotic lesions than in undiseased tissue (Fig. 2C, D). No lesions were observed in wild type mice on high cholesterol diet. In apoE−/− mice, plaque signal intensities were highest for PS-40, followed by PS-25 (Fig. 2C, D). However, when the plaque target-to-background ratio was compared, diagnostic values were observed for all three sensors, ranging from 4.76 ± 0.56 for PS-5 to 7.13 ± 1.36 for PS-40 (Fig. 2E). In contrast, control, wild type mice on normal and high fat diet showed an up to 6-fold lower target (aortic root) to background (descending aorta) ratio (Fig. 2E, p<0.05 vs. apoE−/−). To investigate the regional activation profile of the 3 sensors, apoE−/−mice were coinjected with PS-5 or PS-40 and PS-25 derivatized with a higher wavelength fluorochrome for spectrally resolved imaging. The activation profile was comparable with small

In vivo FMT-CT detects activation in aortic root

We next followed activation of the three probes by serial in vivo FMT-CT imaging. The concept of hybrid imaging is illustrated in apoE−/− mice in Fig. 3A–C. Fiducial markers were readily identified on the imaging cartridge in both modalities and allowed co-registration of data sets in an automated fashion. CT angiography allowed to identify the aortic root as the vascular territory with highest protease activity. Representative 2 and 3 dimensional data sets are shown in Fig. 3D–U. CT imaging also showed vascular calcifications (Fig. 3G and 3H). The in vivo signal time course was followed for each protease sensor over time and is depicted in Fig. 3V. Highest fluorescence concentrations were measured for PS-40 at 24 hours after injection, followed by PS-25 (Fig. 3W). PS-5 had the fastest wash-in and wash-out kinetics. Much lower signals were observed in mice without atherosclerosis, and all three sensors detected protease activity in vivo. However, PS-40 showed the highest fluorescence in plaques.

Figure 3
In vivo FMT-CT

Immunoreactive protease presence colocalizes with PS activation

The microscopic signal distribution was compared to immunoreactive staining for cathepsin B (Fig. 4). There was good co-localization of probe activation with immunofluorescent cathepsin B signal.

Figure 4
Microscopic mapping of probe activation

Cellular target profile by flow cytometry

Flow cytometric profiling identified monocyte/ macrophages as the dominant cellular signal source for all sensors in plaques (Fig. 5). The highest mean fluorescence intensity was observed for PS-40. Some uptake of PS-5 was also seen in neutrophils accumulating in the aortic tissue. Lymphocytes and cells that constitute the aortic wall, e.g. endothelial cells and fibroblasts showed very low signal. In the blood, we observed considerable differences in signal profiles for respective sensors. Whereas there was virtually no activation of PS-5, we observed intermediate and high fluorescence signals in monocytes after injection of PS-25 and PS-40, respectively (Fig. 5).

Figure 5
Flow cytometric profiling of cellular signal contributions

PS-40 detects therapy effects in vivo

Having identified PS-40 as the sensor with superior sensitivity, we further explored its use for non-invasive detection of reduced inflammation in plaque after statin therapy. Atorvastatin is known to reduce the recruitment of inflammatory monocytes, in part through reduction of VCAM-1 expression.22 These cells and their lineage descendants are the primary source of plaque cathepsin1, 10 and together, dominate activation of PS-40 in vivo. Thus, we used FMT-CT for imaging of apoE−/− mice treated with atorvastatin. 24 hours after injection of PS-40, (i.e., at the peak of protease signal intensity), we observed a 2.6-fold reduced FMT signal in the aortic root in treated mice (p < 0.05, Fig. 6 A-C). These data corroborated with ex vivo FRI of excised aortas (Fig. 6D–E) and with quantitative PCR for expression of the model protease cathepsin B (Fig. 6F). As expected in apoE−/− mice, cholesterol blood levels were mildly reduced by atorvastatin treatment (Fig. 6G).

Figure 6
FMT-CT detection of therapy with PS-40

Discussion

Fluorescence molecular tomography is an emerging modality increasingly used in preclinical imaging.14 Here we addressed two obstacles that have limited the utility of FMT to image murine models of atherosclerosis. First, we used an imaging cartridge in free space FMT to merge molecular data with detailed anatomic information provided by high resolution CT angiography. Second, we show that sensitivity, target to background ratio and the pharmacokinetic profile of nano-engineered fluorescent probes can be specifically tailored to meet the demands of individual imaging applications.

Combination of molecular sensing by FMT with anatomical CT imaging in a hybrid set-up was achieved based on landmark-facilitated image co-registration. FMT imaging was immediately followed by CT, while the anesthetized mouse was transferred in a multimodal imaging cartridge that i) ensured a constant position of the mouse and ii) provided the fiducials for co-registration on its frame. An optimized CT angiography protocol provided excellent anatomic information of murine vasculature and visualized calcified plaque. The hybrid approach enhanced the quantitative robustness of in vivo FMT imaging because the region of interest for signal quantification was chosen based on anatomic detail provided by CT, in this case the aortic root, rather than signal intensity. Re-identification of this landmark in serial imaging allowed us to follow protease activity in individual lesions over time. We anticipate that this will prove particularly useful for investigations of experimental anti-inflammatory therapies.

The design for protease sensors closely positions fluorochromes on a nano-scaffold to induce auto-quenching.13 The nanomaterial includes polypeptides as substrate sequences for proteases. In this study, an oligo-L-lysine peptide sequence was used that is primarily cleaved by cathepsins. In the presence of the active protease, cleavage occurs and fluorochromes are liberated and unquenched and therefore can emit fluorescence. This design harbors a powerful amplification strategy, since one moiety of active enzyme can cleave and activate multiple targets. While using an identical activation mechanism, we modified the size of the sensors and the number of attached fluorochromes, and in the case of PS-40, used an iron oxide nanoparticle as a central core, giving rise to unique properties each agent exhibited.

PS-40 had the longest plasma half life and slowest wash out from atherosclerotic plaques. The dextran-coated iron oxide core, which is comparably large in size (40 nm), increased the blood half life and likely promoted cellular retention of activated probe in target tissue after interaction with proteases, whereas smaller cleavage products of PS-25 and PS-5 were washed out faster. The function of PS-40's core as a ‘cellular anchor’ for activated fluorochromes resulted in high signal intensities in atherosclerotic plaques in and ex vivo. As a consequence, the improved sensitivity of PS-40 facilitated non-invasive detection of protease activity modulated by therapy, highlighting the value of FMT-CT for preclinical R&D efforts.

Fluorescence penetrates a limited depth of tissue.7 Therefore, intravascular sensing of protease activity has been performed successfully in animal models,24 with the aim of translating identification of inflamed plaques into the cath lab. For this application, minimized blood background fluorescence is essential to facilitate sensing of signal in the vessel wall. Flow cytometric analysis showed that PS-5 had minimal uptake into circulating leukocytes. In addition, PS-5 exhibited fast kinetics that would allow for clinically desirable rapid injection-imaging sequences. Another application that benefits from the low blood background signal afforded by PS-5 is flow cytometric profiling of cell suspensions dislodged from solid tissues.8, 9, 25 While tissue is usually rinsed prior to enzymatic digestion, some contamination with blood is inevitable. As PS-5 showed no uptake into circulating blood cells, it minimizes this interference.

We used pharmacokinetic data to model in vivo signal in atherosclerotic plaques. The model accounted for agent dose, plasma clearance, pinocytosis rate in activated macrophages, macrophage plaque density, and probe retention in the plaque. There was good agreement between the model predictions and experimental data, providing evidence that the mechanisms used in the model determine the probe behavior in vivo. In-silico experimentation indicated that further increases in plasma half-life have diminishing returns on signal intensity and would increase the necessary delay between injection and imaging at the time of maximum plaque signal. The mechanism-based model can be used to examine any probe design, including addition of targeting ligands or scale-up from mouse to man without the requirement for allometric scaling or empirical assumptions.

In summary, we show that nanotechnology-enabled tailoring of protease sensors optimizes imaging agent design for specific applications. The use of a nanoparticulate ‘cell anchor’ for PS-40 enhanced sensitivity and enabled non-invasive FMT-CT imaging of treatment effects. We anticipate that the use of this sensor in conjunction with hybrid FMT-CT imaging will catalyze quantitative in vivo plaque interrogation in mouse models of atherosclerosis frequently used in basic research and drug development.

Supplementary Material

01

Acknowledgements

The authors acknowledge the help of the CSB Mouse Imaging Program (Edmund Keliher, PhD) and Wael Yared, PhD for helpful discussions. Yoshiko Iwamoto, BS, is acknowledged for help with histology. Jihong Wang, PhD is acknowledged for performing in vitro activation experiments.

Funding sources

This work was funded in part by R24-CA92782 and UO1-HL08073 (to RW) and by the American Heart Association 0835623D (to MN).

Footnotes

Disclaimer: The manuscript and its contents are confidential, intended for journal review purposes only, and not to be further disclosed.

Author Disclosures

Matthias Nahrendorf:
  Research Grant:American Heart Association, Amount: < $10,000
Peter Waterman:
  Ownership Interest:Visen Medical, Amount: < $10,000
Greg Thurber: No disclosures
Kevin Groves:
  Institution/Employer:Visen Medical, Amount: >= $10,000
Milind Rajopadhye:
  Institution/Employer:Visen Medical, Amount: >= $10,000
Peter Panizzi: No disclosures
Brett Marinelli: No disclosures
Elena Aikawa: No disclosures
Mikael Pittet: No disclosures
Filip Swirski: No disclosures
Ralph Weissleder:
  Research Grant:NIH grant, Amount: >= $10,000
  Ownership Interest:Visen Medical, Amount: >= $10,000
  Consultant/Advisory Board:Visen Medical, Amount: < $10,000

Conflict of Interest Disclosures

Kevin Groves and Millind Rajopadhye are employees of VisEn Medical. Ralph Weissleder is a consultant to VisEn Medical. Ralph Weissleder and Peter Waterman hold VisEn shares.

References

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874. [PubMed]
2. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008;451:953–957. [PubMed]
3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–671. [PubMed]
4. Zhang J, Nie L, Razavian M, Ahmed M, Dobrucki LW, Asadi A, Edwards DS, Azure M, Sinusas AJ, Sadeghi MM. Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation. 2008;118:1953–1960. [PMC free article] [PubMed]
5. Schafers M, Riemann B, Kopka K, Breyholz HJ, Wagner S, Schafers KP, Law MP, Schober O, Levkau B. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation. 2004;109:2554–2559. [PubMed]
6. Amirbekian V, Aguinaldo JG, Amirbekian S, Hyafil F, Vucic E, Sirol M, Weinreb DB, Le GreneurS, Lancelot E, Corot C, Fisher EA, Galis ZS, Fayad ZA. Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo. Radiology. 2009;251:429–438. [PMC free article] [PubMed]
7. Ntziachristos V, Tung CH, Bremer C, Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nat Med. 2002;8:757–760. [PubMed]
8. Nahrendorf M, Sosnovik DE, Waterman P, Swirski FK, Pande AN AikawaE, Figueiredo JL, Pittet MJ, Weissleder R. Dual channel optical tomographic imaging of leukocyte recruitment and protease activity in the healing myocardial infarct. Circ Res. 2007;100:1218–1225. [PubMed]
9. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204:3037–3047. [PMC free article] [PubMed]
10. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:1359–1366. [PubMed]
11. Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, Huang PL, Weissleder R. In vivo imaging of proteolytic activity in atherosclerosis. Circulation. 2002;105:2766–2771. [PubMed]
12. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008;452:580–589. [PMC free article] [PubMed]
13. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med. 2003;9:123–128. [PubMed]
14. Sinusas AJBF, Nahrendorf M, Epstein FH, Wu JC, Villanueva FS, Fayad ZA, Gropler RJ. Multimodality Cardiovascular Molecular Imaging, Part I. Circ Cardiovasc Imaging. 2008;1:244–256. [PubMed]
15. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, Libby P, Swirski FK, Weissleder R. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008;117:379–387. [PMC free article] [PubMed]
16. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, Rafique A, Hargeaves R, Farkouh M, Fuster V, Fayad ZA. Atherosclerosis Inflammation Imaging with 18F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations. J Nucl Med. 2008;49:871–878. [PubMed]
17. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnstrom P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708–2711. [PubMed]
18. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol. 2005;23:1418–1423. [PubMed]
19. Verschuren L, Kleemann R, Offerman EH, Szalai AJ, Emeis SJ, Princen HM, Kooistra T. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol. 2005;25:161–167. [PubMed]
20. Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol. 2004;24:1006–1014. [PubMed]
21. Itskovich VV, Choudhury RP, Aguinaldo JG, Fallon JT, Omerhodzic S, Fisher EA, Fayad ZA. Characterization of aortic root atherosclerosis in ApoE knockout mice: high-resolution in vivo and ex vivo MRM with histological correlation. Magn Reson Med. 2003;49:381–385. [PubMed]
22. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation. 2006;114:1504–1511. [PubMed]
23. Bazin-Redureau M, Pepin S, Hong G, Debray M, Scherrmann JM. Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. Toxicol Appl Pharmacol. 1998;150:295–300. [PubMed]
24. Jaffer FA, Vinegoni C, John MC, Aikawa E, Gold HK, Finn AV, Ntziachristos V, Libby P, Weissleder R. Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation. 2008;118:1802–1809. [PMC free article] [PubMed]
25. Nahrendorf MSD, French B, Swirski FK, Bengel F, Sadeghi MM, Lindner JR, Wu JC, Kraitchman DL, Fayad ZA, Sinusas AJ. Multimodality Cardiovascular Molecular Imaging, Part II. Circ Cardiovasc Imaging. 2009;2:56–70. [PMC free article] [PubMed]
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...